Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$2.01 USD
-0.03 (-1.47%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.00 -0.01 (-0.50%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Athira Pharma, Inc. (ATHA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.30 | $19.00 | $3.50 | 306.86% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Athira Pharma, Inc. comes to $8.30. The forecasts range from a low of $3.50 to a high of $19.00. The average price target represents an increase of 306.86% from the last closing price of $2.04.
Analyst Price Targets (5 )
Broker Rating
Athira Pharma, Inc. currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 60%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
8/11/2023 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 5 |
Average Target Price | $8.30 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -0.80 |